Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.

You may also be interested in...



Novartis Lines Up $1 Billion For China R&D

Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space

Novartis Lines Up $1 Billion For China R&D

Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space

Novartis Lines Up $1 Billion For China R&D

In-country research staff will increase over six-fold to approximately 1,000.

Related Content

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel